job losses

News

Novartis sheds MorphoSys staff, sites after pelabresib delay

Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.

News

Editas axes two-thirds of its staff, including its CMO

Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.

News

Mulvany hits the reset button at BenevolentAI

The shape of BenevolentAI following the return of co-founder Ken Mulvany has started to crystallise and could see the company return to private hands.

News

Alligator slashes workforce and pares down its pipeline

Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce.

News

Medigene axes staff and refocuses its TCR pipeline

Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline

News

23andMe ends drug development and slashes staff

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.

Novartis sheds MorphoSys staff, sites after pelabresib delay

Editas axes two-thirds of its staff, including its CMO

Mulvany hits the reset button at BenevolentAI

Alligator slashes workforce and pares down its pipeline

Medigene axes staff and refocuses its TCR pipeline

23andMe ends drug development and slashes staff

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

job losses

Editor's Picks